Press Release 26 September, 2022
During the first half of 2022, Realheart performed successful implantations of its total artificial heart in sheep. These implantations are part of a series of implants to test the clinical version of Realheart® TAH. The next implant has been scheduled to take place in October.
Preparations for this third implant of the clinical Realheart® TAH version are underway and the implantation will be carried out in an animal laboratory in Belgium by three experienced heart surgeons who have also performed the first two implantations: Dr Dilek Gürsoy, Dr Joeri van Puyvelde, and Professor Bart Meyns.
“We have chosen to work with the best surgeons, and I am pleased that we have been able to find a date when all three are available," said Ina Laura Perkins, CEO of Realheart.
The version of the TAH that is being tested is the same one that the company intends to use in human clinical trials expected to start in 2024.
For more information please contact:
Ina Laura Perkins, CEO
Phone: +46(0)70 406 49 21
Certified Adviser: Svensk Kapitalmarknadsgranskning AB, Phone: +46 11 32 30 732, email: email@example.com
Scandinavian Real Heart AB develops a total artificial heart (TAH) for implantation in patients with life-threatening heart failure. Realheart® TAH has a patented design that resembles that of the natural human heart. The artificial heart consists of a four-chamber system (two atria and two ventricles) designed to generate a physiological blood flow pattern that mimics the body's natural circulation. A unique concept in the medical technology world.Third Implantation in Sheep Scheduled to Take Place in October (PDF)